Neurogen Biomarking Announces Partnership with Aranscia
Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen's Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and Alzheimer's Dementia
CHICAGO and HOUSTON, May 21, 2025 /PRNewswire/ -- Neurogen Biomarking, the world's first ecosystem for memory loss with end-to-end patient support, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership in which Aranscia's technical and laboratory resources will help to deliver clinical insights and HIPAA-compliant connectivity for the Neurogen Biomarking ecosystem.
Under this partnership, AccessDx Laboratory, an Aranscia company, will provide Neurogen with technical, operational, and analytical support resources for its blood-based biomarker test that measures phosphorylated tau (p-tau) 217, a specific marker for Alzheimer's disease pathology. AccessDx Laboratory is a CAP-accredited, CLIA-certified, NYSDOH-approved diagnostic laboratory focused on both the development and scaling of novel diagnostic programs.
In addition, 2bPrecise, another Aranscia company, will provide Neurogen with software-based, EMR-agnostic clinical workflow utilities that help to securely integrate Neurogen's diagnostic results and programmatic insights across the Neurogen ecosystem and within a wide range of clinical care settings. 2bPrecise's HIPAA-compliant software solutions currently support thousands of discrete client groups, including leading health systems, municipalities, ACOs, and multi-provider organizations.
"Neurogen's driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a scientifically and clinically controlled ecosystem while also guiding them every step of the way in their brain health journey," said Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking. "Aranscia's proven experience in supporting a wide range of complex diagnostic and clinical workflows, combined with their expertise in enabling innovative and secure end-to-end personalized diagnostic programs, makes them the ideal partner to help us both achieve our objectives and position for scale."
Neurogen's platform is the first patient-initiated system designed to shift the paradigm of early detection of Alzheimer's disease (AD) through improved access to innovative blood biomarker testing and AI-enhanced digital and cognitive assessments. Board-certified neurologists will support eligible Neurogen patients every step of the way via telehealth, providing follow-up care if indicated and accelerating access to expert cognitive care - delivered in weeks rather than the months-long wait times typically seen in traditional neurology care.
"We're proud to partner with Neurogen on its mission to accelerate early detection and interventionist care in the fight against Alzheimer's disease, which has become all too personal for millions of Americans and their families," said Bryon Cipriani, CEO of Aranscia. "This partnership builds upon the foundational efforts of AccessDx Laboratory and 2bPrecise in helping to democratize access to personalized and precision care for all, and in ways that proactively and positively impacts the lives of the patients we help to serve."
Aranscia joins Neurogen's collaborators Linus Health, which is providing the cutting-edge digital cognitive assessments for patients with memory concerns on the Neurogen Biomarking platform; Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection; and NeuroX, a venture of American TelePhysicians, to provide virtual neurology services that help guide the patient journey on its brain health care ecosystem. The platform will be widely available in mid-2025 for anyone with eligible memory and thinking concerns.
Approximately 7 million Americans aged 65 and older were living with Alzheimer's dementia in 2024. It is estimated that 40% of Americans age 65+ experience memory impairment, affecting around 16 million people. Only 8% of Americans living with mild cognitive impairment receive a diagnosis, leaving 92% undiagnosed. The process of developing Alzheimer's disease is slow, with 15-20 years before the onset of Mild Cognitive Impairment (MCI). MCI precedes Alzheimer's disease by many years.
About Neurogen Biomarking
Neurogen Biomarking is dedicated to supporting early detection of Alzheimer's disease and Mild Cognitive Impairment. Founded by award-winning neurologist, Dr. Rany Aburashed and guided by world-renowned brain health experts, Neurogen is on a mission to empower anyone with thinking and memory concerns with the tools, education, and motivation needed to access advanced, personalized care of patients with Alzheimer's disease – and a future with more in it. To learn more visit www.neurogenbiomarking.com or follow us on LinkedIn.
About Aranscia
Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia's portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit www.aranscia.com.
Media Contacts:
Neurogen Biomarking
395551@email4pr.com
872.240.3696
Aranscia
395551@email4pr.com
516.317.5835
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurogen-biomarking-announces-partnership-with-aranscia-302461276.html
SOURCE Aranscia